Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Lancet Planet Health ; 7(1): e23-e32, 2023 01.
Artigo em Inglês | MEDLINE | ID: mdl-36608945

RESUMO

BACKGROUND: Unhealthy diet, physical inactivity, and social disconnection are important modifiable risk factors for non-communicable and other chronic diseases, which might be alleviated through nature-based community interventions. We tested whether a community gardening intervention could reduce these common health risks in an adult population that is diverse in terms of age, ethnicity, and socioeconomic status. METHODS: In this observer-blind, randomised, controlled trial, we recruited individuals who were on Denver Urban Garden waiting lists for community gardens in Denver and Aurora (CO, USA), aged 18 years or older, and had not gardened in the past 2 years. Participants were randomly assigned (1:1), using a randomised block design in block sizes of two, four, or six, to receive a community garden plot (intervention group) or remain on a waiting list and not garden (control group). Researchers were masked to group allocation. Primary outcomes were diet, physical activity, and anthropometry; secondary outcomes were perceived stress and anxiety. During spring (April to early June, before randomisation; timepoint 1 [T1]), autumn (late August to October; timepoint 2 [T2]), and winter (January to March, after the intervention; timepoint 3 [T3]), participants completed three diet recalls, 7-day accelerometry, surveys, and anthropometry. Analyses were done using the intention-to-treat principle (ie, including all participants randomly assigned to groups, and assessed as randomised). We used mixed models to test time-by-intervention hypotheses at an α level of 0·04, with T2 and T3 intervention effects at an α level of 0·005 (99·5% CI). Due to potential effects of the COVID-19 pandemic on outcomes, we excluded all participant data collected after Feb 1, 2020. This study is registered with ClinicalTrials.gov, NCT03089177, and data collection is now complete. FINDINGS: Between Jan 1, 2017, and June 15, 2019, 493 adults were screened and 291 completed baseline measures and were randomly assigned to the intervention (n=145) or control (n=146) groups. Mean age was 41·5 years (SD 13·5), 238 (82%) of 291 participants were female, 52 (18%) were male, 99 (34%) identified as Hispanic, and 191 (66%) identified as non-Hispanic. 237 (81%) completed measurements before the beginning of the COVID-19 pandemic. One (<1%) participant in the intervention group had an adverse allergic event in the garden. Significant time-by-intervention effects were observed for fibre intake (p=0·034), with mean between-group difference (intervention minus control) at T2 of 1·41 g per day (99·5% CI -2·09 to 4·92), and for moderate-to-vigorous physical activity (p=0·012), with mean between-group difference of 5·80 min per day (99·5% CI -4·44 to 16·05). We found no significant time-by-intervention interactions for combined fruit and vegetable intake, Healthy Eating Index (measured using Healthy Eating Index-2010), sedentary time, BMI, and waist circumference (all p>0·04). Difference score models showed greater reductions between T1 and T2 in perceived stress and anxiety among participants in the intervention group than among those in the control group. INTERPRETATION: Community gardening can provide a nature-based solution, accessible to a diverse population including new gardeners, to improve wellbeing and important behavioural risk factors for non-communicable and chronic diseases. FUNDING: American Cancer Society, University of Colorado Cancer Centre, University of Colorado Boulder, National Institutes of Health, US Department of Agriculture National Institute of Food and Agriculture, Michigan AgBioResearch Hatch projects.


Assuntos
COVID-19 , Jardinagem , Estados Unidos , Adulto , Humanos , Masculino , Feminino , Pandemias , Dieta , Exercício Físico
2.
J Pers Med ; 11(10)2021 Sep 29.
Artigo em Inglês | MEDLINE | ID: mdl-34683123

RESUMO

Simulation technologies offer interesting opportunities for computer planning of orthognathic surgery. However, the methods used to date require tedious set up of simulation meshes based on patient imaging data, and they rely on complex simulation models that require long computations. In this work, we propose a modeling and simulation methodology that addresses model set up and runtime simulation in a holistic manner. We pay special attention to modeling the coupling of rigid-bone and soft-tissue components of the facial model, such that the resulting model is computationally simple yet accurate. The proposed simulation methodology has been evaluated on a cohort of 10 patients of orthognathic surgery, comparing quantitatively simulation results to post-operative scans. The results suggest that the proposed simulation methods admit the use of coarse simulation meshes, with planning computation times of less than 10 seconds in most cases, and with clinically viable accuracy.

3.
Future Microbiol ; 15: 633-648, 2020 05.
Artigo em Inglês | MEDLINE | ID: mdl-32495698

RESUMO

Aim: We explored the feasibility of collecting and analyzing human microbiome data in a longitudinal randomized controlled trial of community gardening. Methods & materials: Participants were randomly assigned to gardening (N = 8) or control (N = 8). Participants provided stool, mouth, hand and forehead microbiome samples at six timepoints. Analyses combined mixed models with Qiita output. Results: Participant satisfaction was high, with 75% of participants completing evaluations. While no microbial effects were statistically significant due to small sample size, the analysis pipeline utility was tested. Conclusion: Longitudinal collection and analysis of microbiome data in a community gardening randomized controlled trial is feasible. The analysis pipeline will be useful in larger studies for assessment of the pathway between microbiota, gardening and health outcomes.


Assuntos
Jardinagem , Microbiota , Adulto , Bactérias/classificação , Bactérias/genética , Bactérias/isolamento & purificação , Estudos de Viabilidade , Fezes/microbiologia , Feminino , Testa/microbiologia , Promoção da Saúde , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Boca/microbiologia , Características de Residência/estatística & dados numéricos , Adulto Jovem
4.
Sci Rep ; 7: 41510, 2017 01 31.
Artigo em Inglês | MEDLINE | ID: mdl-28139717

RESUMO

Iron deficiency has been associated with kidney injury. Deferasirox is an oral iron chelator used to treat blood transfusion-related iron overload. Nephrotoxicity is the most serious and common adverse effect of deferasirox and may present as an acute or chronic kidney disease. However, scarce data are available on the molecular mechanisms of nephrotoxicity. We explored the therapeutic modulation of deferasirox-induced proximal tubular cell death in culture. Deferasirox induced dose-dependent tubular cell death and AnexxinV/7AAD staining showed features of apoptosis and necrosis. However, despite inhibiting caspase-3 activation, the pan-caspase inhibitor zVAD-fmk failed to prevent deferasirox-induced cell death. Moreover, zVAD increased deferasirox-induced cell death, a feature sometimes found in necroptosis. Electron microscopy identified mitochondrial injury and features of necrosis. However, neither necrostatin-1 nor RIP3 knockdown prevented deferasirox-induced cell death. Deferasirox caused BclxL depletion and BclxL overexpression was protective. Preventing iron depletion protected from BclxL downregulation and deferasirox cytotoxicity. In conclusion, deferasirox promoted iron depletion-dependent cell death characterized by BclxL downregulation. BclxL overexpression was protective, suggesting a role for BclxL downregulation in iron depletion-induced cell death. This information may be used to develop novel nephroprotective strategies. Furthermore, it supports the concept that monitoring kidney tissue iron depletion may decrease the risk of deferasirox nephrotoxicity.


Assuntos
Apoptose/efeitos dos fármacos , Benzoatos/farmacologia , Regulação para Baixo/efeitos dos fármacos , Ferro/metabolismo , Túbulos Renais Proximais/metabolismo , Túbulos Renais Proximais/patologia , Triazóis/farmacologia , Proteína bcl-X/metabolismo , Animais , Caspase 3/metabolismo , Sobrevivência Celular/efeitos dos fármacos , Citoproteção/efeitos dos fármacos , Deferasirox , Ativação Enzimática/efeitos dos fármacos , Túbulos Renais Proximais/ultraestrutura , Camundongos , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Mitocôndrias/ultraestrutura , Modelos Biológicos , Necrose , Proteína Serina-Treonina Quinases de Interação com Receptores/metabolismo , Estresse Fisiológico/efeitos dos fármacos
7.
Mol Genet Metab ; 114(2): 248-58, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25468652

RESUMO

Lysosomal α-galactosidase A (α-Gal) is the enzyme deficient in Fabry disease (FD), an X-linked glycosphingolipidosis caused by pathogenic mutations affecting the GLA gene. The early-onset, multi-systemic FD classical phenotype is associated with absent or severe enzyme deficiency, as measured by in vitro assays, but patients with higher levels of residual α-Gal activity may have later-onset, more organ-restricted clinical presentations. A change in the codon 118 of the wild-type α-Gal sequence, replacing basic arginine by a potentially sulfhydryl-binding cysteine residue - GLA p.(Arg118Cys) -, has been recurrently described in large FD screening studies of high-risk patients. Although the Cys118 allele is associated with high residual α-Gal activity in vitro, it has been classified as a pathogenic mutation, mainly on the basis of theoretical arguments about the chemistry of the cysteine residue. However its pathogenicity has never been convincingly demonstrated by pathology criteria. We reviewed the clinical, biochemical and histopathology data obtained from 22 individuals of Portuguese and Spanish ancestry carrying the Cys118 allele, including 3 homozygous females. Cases were identified either on the differential diagnosis of possible FD manifestations and on case-finding studies (n=11; 4 males), or on unbiased cascade screening of probands' close relatives (n=11; 3 males). Overall, those data strongly suggest that the GLA p.(Arg118Cys) variant does not segregate with FD clinical phenotypes in a Mendelian fashion, but might be a modulator of the multifactorial risk of cerebrovascular disease. The Cys118 allelic frequency in healthy Portuguese adults (n=696) has been estimated as 0.001, therefore not qualifying for "rare" condition.


Assuntos
Doença de Fabry/diagnóstico , Doença de Fabry/etnologia , Rim/patologia , alfa-Galactosidase/genética , Adulto , Alelos , Substituição de Aminoácidos , Códon/genética , Doença de Fabry/complicações , Doença de Fabry/epidemiologia , Saúde da Família , Feminino , Frequência do Gene , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Estrutura Molecular , Mutação , Fenótipo
9.
Nat Rev Nephrol ; 10(10): 574-86, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25048549

RESUMO

In 2005, the oral iron chelator deferasirox was approved by the FDA for clinical use as a first-line therapy for blood-transfusion-related iron overload. Nephrotoxicity is the most serious and frequent adverse effect of deferasirox treatment. This nephrotoxicity can present as an acute or chronic decrease in glomerular filtration rate (GFR). Features of proximal tubular dysfunction might also be present. In clinical trials and observational studies, GFR is decreased in 30-100% of patients treated with deferasirox, depending on dose, method of assessment and population studied. Nephrotoxicity is usually nonprogressive and/or reversible and rapid iron depletion is one of several risk factors. Scarce data are available on the molecular mechanisms of nephrotoxicity and the reasons for the specific proximal tubular sensitivity to the drug. Although deferasirox promotes apoptosis of cultured proximal tubular cells, the trigger has not been well characterized. Observational studies are required to track current trends in deferasirox prescription, assess the epidemiology of deferasirox nephrotoxicity in routine clinical practice, explore the effect on outcomes of various monitoring and dose-adjustment protocols and elucidate the long-term consequences of the different features of nephrotoxicity. Deferasirox nephrotoxicity can be more common in the elderly; thus, specific efforts should be dedicated to investigate the effect of deferasirox use in this group of patients.


Assuntos
Injúria Renal Aguda/induzido quimicamente , Benzoatos/efeitos adversos , Taxa de Filtração Glomerular , Quelantes de Ferro/efeitos adversos , Sobrecarga de Ferro/tratamento farmacológico , Insuficiência Renal Crônica/induzido quimicamente , Triazóis/efeitos adversos , Deferasirox , Humanos , Sobrecarga de Ferro/etiologia , Reação Transfusional
10.
Nefrología (Madr.) ; 34(3): 317-322, mayo-jun. 2014. tab
Artigo em Espanhol | IBECS | ID: ibc-126601

RESUMO

El carcinoma tiroideo es una neoplasia que tiene una incidencia más alta en pacientes con enfermedad renal crónica. Durante los últimos años se ha avanzado en las pruebas diagnósticas y terapéuticas. Los pacientes de diálisis son un grupo particular, al ser detectado el cáncer de forma indirecta en el estudio del hiperparatiroidismo secundario y durante el estudio previo al trasplante renal. La tiroidectomía es el tratamiento definitivo, pero en pacientes con riesgo de recidiva es necesaria la terapia ablativa con yodo radioactivo I-131, que es predominantemente excretado por vía renal, por lo que su uso en pacientes en diálisis supone un problema de dosificación. Se presentan dos casos de pacientes en hemodiálisis sometidos a radioablación con yodo radiactivo I-131, que con un manejo multidisplinar produjo los resultados esperados en los pacientes (AU)


Thyroid carcinoma is a neoplasia with a higher incidence in patients with chronic kidney disease. In recent years advances have been made in diagnostic and therapeutic trials. Dialysis patients are a particular group, their cancer being detected indirectly in the study of secondary hyperparathyroidism and during the study prior to renal transplantation. Thyroidectomy is the definitive treatment, but in patients with risk of recurrence, ablative therapy is required using radioactive iodine I-131, which is predominantly eliminated by renal excretion, therefore its use in patients on dialysis poses a problem in terms of dosage. Two cases are presented of patients on haemodialysis undergoing radioablation with radioactive iodine I-131, which with multidisciplinary treatment had the expected results in the patients (AU)


Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Insuficiência Renal Crônica/complicações , Hiperparatireoidismo Secundário/complicações , Neoplasias da Glândula Tireoide/radioterapia , Tireoidectomia , Análise por Ativação/métodos , Radioisótopos do Iodo/uso terapêutico , 3-Iodobenzilguanidina/uso terapêutico
11.
Nefrologia ; 34(3): 317-22, 2014 May 21.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-24798564

RESUMO

Thyroid carcinoma is a neoplasia with a higher incidence in patients with chronic kidney disease. In recent years advances have been made in diagnostic and therapeutic trials. Dialysis patients are a particular group, their cancer being detected indirectly in the study of secondary hyperparathyroidism and during the study prior to renal transplantation. Thyroidectomy is the definitive treatment, but in patients with risk of recurrence, ablative therapy is required using radioactive iodine I-131, which is predominantly eliminated by renal excretion, therefore its use in patients on dialysis poses a problem in terms of dosage. Two cases are presented of patients on haemodialysis undergoing radioablation with radioactive iodine I-131, which with multidisciplinary treatment had the expected results in the patients.


Assuntos
Radioisótopos do Iodo/uso terapêutico , Falência Renal Crônica/complicações , Falência Renal Crônica/terapia , Diálise Renal , Neoplasias da Glândula Tireoide/complicações , Neoplasias da Glândula Tireoide/radioterapia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
13.
Dermatol. venez ; 33(4): 159-65, 1995. ilus
Artigo em Espanhol | LILACS | ID: lil-185658

RESUMO

Un tumor maligno puede manifestarse externamente en piel y su reconocimiento puede conducir al diagnóstico de una neoplasia previamente no sospechada. Es difícil determinar la frecuenticia exacta de todos los síndromes paraneoplásicos debido a: distintas definiciones, etiologías desconocidas y la falta de estudios controlados sistemáticos. Se presenta un estudio clínico descriptivo sobre las manifestaciones cutáneas paraneoplásicas en pacientes con carcinoma pulmonar; para ello se evaluaron los pacientes que ingresaron con el diagnóstico de cáncer de pulmón o a quienes se les hizo este diagnóstico durante su hospitalización en el Hospital José Ignacio Baldó en el lapso noviembre/92-junio/94 y que presentaran alguna dermatosis. La muestra estuvo compuesta por 48 pacientes de los cuales 5 presentaron manifestaciones paraneoplásicas, a saber: tromboflebitis superficial (2 casos), ictiosis adquirida, esclerodermia y prurito generalizado con un caso cada uno. Estas condiciones son discutidas con amplitud


Assuntos
Adulto , Pessoa de Meia-Idade , Humanos , Masculino , Feminino , Adenocarcinoma , Neoplasias Pulmonares/diagnóstico , Síndromes Paraneoplásicas/diagnóstico , Neoplasias Cutâneas/diagnóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...